Associate Professor Natalie Staplin
Natalie Staplin
PhD
MRC PHRU Senior Statistician
Natalie is a Senior Statistician within the Renal Studies Group at the Clinical Trials Service Unit & Epidemiological Studies Unit (CTSU). She is also a lecturer on the MSc in Global Health Sciences. She joined CTSU in 2012 after completing an undergraduate degree in Mathematics with Actuarial Science and a PhD in Statistics. Her current research interests are epidemiological analyses of patients with chronic kidney disease to identify risk factors associated with vascular events or progression to end-stage renal disease. She is particularly interested in competing risks methodology and the use of directed acyclic graphs in observational analyses.
Recent publications
-
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
RECOVERY Collaborative Group None. et al, (2022)
-
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151
-
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Journal article
RECOVERY Collaborative Group None., (2021), The Lancet. Respiratory medicine, 9, 1419 - 1426
-
UMOD-ulating CKD risk: untangling the relationship between urinary uromodulin, blood pressure, and kidney disease
Journal article
Turner M. and Staplin N., (2021), Kidney International, 100, 1168 - 1170
-
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.
Working paper
Horby P. et al, (2021), Lancet, 398